Bibliography


Ambrosone, CB, Sweeney C, Coles BF et al. (2001), Polymorphisms in glutathione S-transferases
(GSTM1 and GSTT1) and survival after treatment for breast cancer, *Cancer Res*, 61, 7130-7135.


Anantharaman D, Chaubal PM, Kannan S et al. (2007), Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: tobacco exposure as a risk modulator, *Carcinogenesis*, 28, 1455-1462.

Ang MK, Patel MR, Yin XY et al. (2011), High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma, *Clin Cancer Res*, 17, 6542-6552.


Bewick MA, Conlon MSC, Lafrenic RM (2006), Polymorphisms in XRCC1, XRCC3 and CCND1


Cantor KP, Villanueva CM, Silverman DT et al. (2010), Polymorphisms in GSTT1, GSTZ1, and CYP2E1, disinfection byproducts, and risk of bladder cancer in Spain, *Environ health Persp,*


Cheng D, Shi H, Zhang K et al. (2014), RAD51 gene 135G/C polymorphism and the risk of four


Cordero K, Espinoza I, Caceres D et al. (2010), Oral cancer susceptibility associated with the CYP1A1 and GSTM1 genotypes in Chilean individuals, Oncology Lett, 1, 549-553.

Costa S, Pinto D, Pereira D et al. (2008), XRCC1 Arg399Gln and RAD51 5'UTR G135C polymorphisms and their outcome in tumor aggressiveness and survival of Portuguese breast cancer patients, Breast Cancer Tr, 109, 183-185.


D’errico A, Taioli E, Chen X et al. (1996), Genetic metabolic polymorphisms and the risk of cancer: a review of the literature, Biomarkers, 1, 149-173.


Divine KK, Gilliland FD, Crowell RE (2001), The XRCC1 399 glutamine allele is a risk factor for


Eifel PJ, Burke TW, Delclos L *et al.* (1991), Early stage I adenocarcinoma of the uterine cervix: treatment results in patients with tumors less than or equal to 4 cm in diameter, *Gynecol Oncol*, 41, 199-205.


Goodman MT, McDuffie K, Hernandez B et al. (2001), CYP1A1, GSTM1 and GSTT1 polymorphisms and the risk of cervical squamous intraepithelial lesions in a multiethnic population, *Gynecol Oncol*, 81, 263-269.


Han J, Hankinson SE, Colditz GA et al. (2004), Genetic variation in XRCC1, sun exposure, and risk of skin cancer, *Br J Cancer*, 91, 1604-1609.


Heinrich MC, Corless CL, Blanke C et al. (2002b), KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs), *Proc


Howells RE, Redman CW, Dhar KK et al. (1998), Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer, *Clin Cancer Res*, 4, 2439-2445.

Hung HC, Chuang J, Chien YC et al. (1997), Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1: environmental factors and risk of oral cancer, Cancer Epidemiology Biomarker & Prevention, 6, 901-905.


Hussein AG, Pasha HF, El-Shahat et al. (2014), CYP1A1 gene polymorphisms and smoking status as modifier factors for lung cancer risk, Gene, 541, 26-30.

ICO Information Centre on HPV and cancer (2014), Human Papillomavirus and Related Diseases in India (Summary Report 2014-08-22).


Inoue M, Kyo S, Fujita M et al. (1994), Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors, Cancer Res, 54, 3049-3053.


Joshi MB, Shirota Y, Danenberg KD et al. (2005), High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer, *Clin Cancer Res*, 11, 2215-2221.


Kato S, Naito Z, Matsuda N et al. (2011), Localization of cytochrome P4502E1 enzyme in normal

Katoh T, Nagata N, Kuroda Y et al. (1996), Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma, *Carcinogenesis*, 17, 1855-1859.


Kim HS, Kim MK, Chung HH et al. (2009), Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study, *Gynecol Oncol*, 113, 264-269.


Kim SU, Park SK, Yoo KY et al. (2002), XRCC1 genetic polymorphism and breast cancer risk,
Pharmacogenetics, 12, 335-338.


Koop DR (1992), Oxidative and reductive metabolism by cytochrome P4502E1, FASEB J, 6, 724–730.


Kumar M, Agarwal SK, Goel SK (2009), Lung cancer risk in North Indian population: Role of genetic polymorphisms and smoking, Mol Cell Biochem, 322, 73-79.

Kumar V, Yadav CS, Singh S et al. (2010), CYP 1A1 polymorphism and organochlorine pesticides levels in the etiology of prostate cancer, Chemosphere, 81, 464-468.


Le Marchand L, Sivaraman L, Pierce L *et al.* (1998), Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens, *Cancer Res*, 58, 4858-4863.
Lee HC, Yoon YB, Kim CY (1997), Association between genetic polymorphisms of the 
cytochromes P-450 (1A1, 2D6, and 2E1) and the susceptibility to pancreatic cancer, *Korean J 

Lee SA, Kim JW, Roh JW et al. (2004), Genetic polymorphisms of GSTM1, p21, p53 and HPV 
infection with cervical cancer in Korean women, *Gynecol Oncol*, 93, 14-18.

Lee SG, Kim B, Choi J et al. (2012), Genetic polymorphisms of XRCC1 and risk of gastric 

Li H, Xiao D, Hu L et al. (2012), Association of CYP1A1 polymorphisms with prostate cancer 

Liang J, Jiang T, Yao RY et al. (2010), The combination of ERCC1 and XRCC1 gene 
polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in 

Liao WY, Shih JY, Chang GC et al. (2012), Genetic polymorphism of XRCC1 Arg399Gln is 
associated with survival in non-small-cell lung cancer patients treated with gemcitabine/ 


Liu G, Ghadirian P, Vesprini D et al. (2000), Polymorphisms in GSTM1, GSTT1 and CYP1A1 
and risk of pancreatic adenocarcinoma, *Br J Cancer*, 82, 1646-1649.

Liu R, Yin LH, Pu YP (2007), Association of combined CYP2E1 gene polymorphism with the 
risk for esophageal squamous cell carcinoma in Huai’an population, China, *Chin Med J*, 120, 
1797-1802.

Liu YP, Ling Y, Zhang YP et al. (2011), Predictive values of platinum-rel`lated gene
polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy,


Marchand LL, Sigfried A, Lum A et al. (1998), Association of CYP1A1, GSTM1 and CYP2E1 polymorphisms with lung cancer suggest cell type specifications to tobacco carcinogens, *Cancer Res*, 58, 4858-4863.


Mir O, Alexandre J, Tran A et al. (2009), Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity, Ann Oncol, 20, 736-740.


Niwa Y, Matsuo K, Ito H et al. (2005), Association of XRCC1 Arg399Gln and OGG1 Ser326Cys polymorphisms with the risk of cervical cancer in Japanese subjects, Gynecol Oncol, 99, 43-49.


Olaharski AJ, Sotelo R, Solorza-Luna G et al. (2006), Tetraploidy and chromosomal instability are early events during cervical carinogenesis, Carcinogenesis 27, 337-343.

Olshan AF, Weissler MC, Watson MA et al. (2000), GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer, Cancer Epidemiol Biomarkers Prev, 9, 185-191.


Ottone F, Miotti S, Bottini C et al. (1997), Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines, Br J Cancer, 76, 77-82.


Ozturk T, Kahraman OT, Toptas B et al. (2011), The effect of CYP1A1 and GSTM1 gene polymorphisms in bladder cancer development in a Turkish population, In Vivo, 25, 663-668.

Palmu S, Soderstrom KO, Quazi K et al. (2002), Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer, Anticancer Res, 22, 411-414.

Park GT, Lee OY, Kwon SJ et al. (2003), Analysis of CYP2E1 polymorphism for the determination of genetic susceptibility to gastric cancer in Koreans, J Gastroenterol Hepatol, 18, 1257-1263.


Parl FF (2005), Glutathione S-transferase genotypes and cancer risk, Cancer Lett, 221, 123-129.

Paul S, Chaudhuri T, Pant MC et al. (2014), Association of cytochrome P450 2C9 polymorphism with locally advanced head and neck squamous cell carcinoma and response to concurrent cisplatin-based radical chemoradiation, South Asian J Cancer, 3, 154-158.


Poppe WAJ, Ide PS, Drijkoningen MPG et al. (1995), Tobacco smoking impairs the local immunosurveillance in the uterine cervix, Gynecol Obstet Invest, 39, 34-38.

Porter TR, Richards FM, Houlston RS et al. (2002), Contribution of cyclin D1 (CCND1) and E-Cadherin(CDH1) polymorphisms to familial and sporadic colorectal cancer, Oncogene, 21,1928-1933.

Potti A, Moazzam N, Ramar K et al. (2003), CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma, Ann Oncol, 14, 894-897.


Ran H, Kefu T, Zhiyun W et al. (2012), Genetic Polymorphisms in CYP2E1: Association with schizophrenia susceptibility and risperidone response in the chinese Han population, PLoS ONE, 7, 1-10.

Rednam S, Scheurer ME, Adesina A et al. (2013), Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma, Pediatr
Blood Cancer, 60, 593-598.
Rolland D, Raharijaona M, Barbarat A et al. (2010), Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin, Anticancer Res, 30, 3951-3957.
Ryu JS, Hong YC, Han HS et al. (2004), Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy, Lung Cancer, 44, 311-316.


Shen M, Hung RJ, Brennan P *et al.* (2003), Polymorphismsof the DNA repair genes XRCC1, XRCC3,XPD, interaction with environmental exposures, andbladder cancer risk in a case-control study in northern Italy, *Cancer Epidemiol Biomarkers Prev*, 12, 1234-1240.

Shi YY and He L (2005), SHEsis is a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci, *Cell Res*, 15, 97-98.


Sobti RC, Kaur S, Kaur P *et al.* (2006), Interaction of passive smoking with GST (GSTM1, GSTT1, and GSTP1) genotypes in the risk of cervical cancer in India, *Cancer Genet*
Cytogenet, 166, 117-123.


Spurdle AB, Webb PM, Purdie DM et al. (2001), Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype, Carcinogenesis, 22, 67-72.

Sreeja L, Vani S, Sreedharan H et al. (2005), Possible risk modification by CYP1A1, GSTM1 and GSTT1 gene polymorphisms in lung cancer susceptibility in a South Indian population, J Hum Genet, 50, 618-627.

Srivastava DS, Mishra DK, Mandhani A et al. (2005), Association of genetic polymorphism of glutathione S-transferase M1, T1, P1 and susceptibility to bladder cancer, Eur Urol, 48, 339-344.

Stanulla M, Schrappe M, Brechlin AM et al. (2000), Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study, Blood, 95, 1222-1228.


Sweeney C, Nazar-Stewart V, Stapleton PL et al. (2003), Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients, *Cancer Epidemiol Biomarkers & Prev*, 12, 527-533.


Tsuchiya Y, Nakajima M, Yokoi T (2005), Cytochrome P450-mediated metabolism of estrogens


Wu MS, Chen CJ, Lin MT et al. (2002), Genetic polymorphisms of cytochrome p450 2E1, glutathione S-transferase M1 and T1, and susceptibility to gastric carcinoma in Taiwan, *Int J Colorectal Dis*, 17, 338-343.

Wu X, Shi H, Jiang H et al. (1997), Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer, *Carcinogenesis (Lond.)*, 8, 967-973.


Yamazaki H, Inui Y, Yun CH et al. (1992), Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of Nnitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes, *Carcinogenesis* 13, 1789-1794.


